"Genomic Health Inc. Nasdaq GHDX httpstudio.financialcontent.comprnewsPageQuoteTickerGHDX today announced that the Journal of Surgical Oncology published results from a multicenter study of the Oncotype DX DCIS Score demonstrating the test has significant impact on the treatment recommendations for patients with ductal carcinoma in situ DCIS also referred to as stage  or preinvasive breast cancer. These study results underscore the practicechanging clinical utility of the test for many of the  women diagnosed with DCIS each year in the United States alone. Most patients with DCIS are treated with surgery followed by radiation yet only about  percent of them are likely to experience a recurrence or develop an invasive form of the disease said Michael Alvarado M.D. associate professor of surgery the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. These results highlight the need to optimize treatment of this noninvasive indolent form of breast disease and the importance of Oncotype DX in helping physicians reduce over and undertreatment of DCIS. DCIS affects one out of every five women diagnosed with breast cancer in the United States and is often treated with surgery followed by radiation therapy andor hormonal therapy. The Oncotype DX DCIS Score result provides patients with an individualized estimate of local in the same breast recurrence which could be either invasive breast cancer or DCIS. This information helps physicians and patients personalize treatment decisions to potentially spare women with low risk of recurrence additional treatment they may not need while identifying women with a higher risk of recurrence who may need additional treatment after surgery. Conducted in collaboration with Partnership for Health Analytic Research this prospective study analyzed  patients from  cancer centers in the United States. The results showed that physician treatment recommendations changed for  percent of patients after receiving the DCIS Score result reducing the number of patients receiving a radiotherapy recommendation by approximately onethird. Importantly of the patients initially recommended not to receive radiotherapy  percent were identified as having a high risk of recurrence and recommended to have radiotherapy. Physicians in this study rated the DCIS Score as the most important factor in planning treatment compared with pathologic features patient preference patient age comorbidities or consultation with other physicians.  The Oncotype DX DCIS Score result was validated in two studies including nearly  patients and is the only genomic test for patients with preinvasive breast cancer said Phil Febbo M.D. chief medical officer Genomic Health. The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS and we believe that these results will support expanded adoption of and access to the DCIS Score. About Oncotype DX The Oncotype DX portfolio of breast colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The companys flagship product the Oncotype DX breast cancer test httpbreastcancer.oncotypedx.com has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer http Additionally the test predicts the likelihood of recurrence in a preinvasive form of breast cancer called DCIS httpbreastcancer.oncotypedx.comenUSPatientDCIS.aspx. With half a million patients tested in more than  countries the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX breast cancer tests visit  http or  http  About Genomic Health Genomic Health http Inc. NASDAQ GHDX httpstudio.financialcontent.comprnewsPageQuoteTickerGHDX is the worlds leading provider of genomicbased diagnostic tests that address both the overtreatment and optimal treatment of earlystage cancer one of the greatest issues in healthcare today. The company is applying its worldclass scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinicallyactionable results for treatment planning throughout the cancer patients journey from diagnosis to treatment selection and monitoring. The company is based in Redwood City http California with European headquarters in Geneva Switzerland. For more information please visit  http and follow the company on Twitter GenomicHealth httpstwitter.comGenomicHealth Facebook http YouTube https and LinkedIn https This press release contains forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of  including statements relating to the benefits of the test to physicians patients and payors. Forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include but are not limited to the ability of test results to change treatment decisions the risks and uncertainties associated with the regulation of the companys tests the results of clinical studies the applicability of clinical study results to actual outcomes the risk that the company may not obtain or maintain sufficient levels of reimbursement domestically or abroad for its existing tests and any future tests it may develop the risks of competition unanticipated costs or delays in research and development efforts and the other risks set forth in the companys filings with the Securities and Exchange Commission including the risks set forth in the companys quarterly report on Form Q for the year ended March  . These forwardlooking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forwardlooking statements. NOTE The Genomic Health logo Oncotype Oncotype DX Recurrence Score and DCIS Score are trademarks or registered trademarks of Genomic Health Inc. All other trademarks and service marks are the property of their respective owners. Logo  httpphotos.prnewswire.comprnhSFLOGO SOURCE Genomic Health Inc. Related Links http"